Suppression of elevated cartilage turnover in postmenopausal women and in ovariectomized rats by estrogen and a selective estrogen-receptor modulator (SERM).

Stephan Christgau; László B Tankó; Paul A C Cloos; Ulrik Mouritzen; Claus Christiansen; Jean-Marie Delaissé; Pernille Høegh-Andersen

Suppression of elevated cartilage turnover in postmenopausal women and in ovariectomized rats by estrogen and a selective estrogen-receptor modulator (SERM).

Stephan Christgau, László B Tankó, Paul A C Cloos, Ulrik Mouritzen, Claus Christiansen, Jean-Marie Delaissé, Pernille Høegh-Andersen

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

117 Citationer (Scopus)

Abstract

Udgivelsesdato: 2004

Originalsprog	Engelsk
Tidsskrift	Menopause
Vol/bind	11
Udgave nummer	5
Sider (fra-til)	508-18
Antal sider	10
ISSN	1072-3714
Status	Udgivet - 2004
Udgivet eksternt	Ja

Bibliografisk note

Keywords: Aged; Analysis of Variance; Animals; Biopsy, Needle; Cartilage, Articular; Disease Models, Animal; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Estrogen Replacement Therapy; Female; Humans; Immunohistochemistry; Middle Aged; Osteoporosis, Postmenopausal; Ovariectomy; Postmenopause; Probability; Prognosis; Pyrrolidines; Rats; Rats, Sprague-Dawley; Risk Assessment; Selective Estrogen Receptor Modulators; Statistics, Nonparametric; Treatment Outcome

Citationsformater

@article{17716a5053f311dd8d9f000ea68e967b,

title = "Suppression of elevated cartilage turnover in postmenopausal women and in ovariectomized rats by estrogen and a selective estrogen-receptor modulator (SERM).",

abstract = "OBJECTIVE: Several observational studies indicate that estrogen deficiency increases the incidence of osteoarthritis in postmenopausal women. To validate this observation, we investigated the effects of ovariectomy (OVX) on cartilage erosion in rats using histology and an established bio-assay of cartilage-specific collagen type II degradation products (CTX-II). Furthermore, we investigated whether estrogen and levormeloxifene, a selective estrogen-receptor modulator (SERM), can prevent the OVX-induced changes in cartilage degradation. The clinical relevance was assessed in postmenopausal women by measuring the changes in CTX-II during 12-month treatment with levormeloxifene versus placebo. DESIGN: Sixty 6-month-old rats were divided in five groups. One group was subjected to sham and the others to OVX, followed by treatment with vehicle alone, estradiol or 0.2 mg/kg/day or 5 mg/kg/day of levormeloxifene. The rats were treated for 9 weeks with biweekly blood and urine sampling for measurement of bone resorption and cartilage turnover. After study termination, hind knees were removed for histological analysis of erosions. The effect of levormeloxifene in post-menopausal women was assessed by measuring CTX-II in samples from 301 women who were participating in a phase II study of this SERM. RESULTS: OVX rats showed significant increases in the urinary excretion of CTX-II. After 9 weeks this was manifested as increased surface erosion of knee articular cartilage compared with sham-operated rats. Treatment with estrogen or levormeloxifene prevented the OVX-induced changes. There was a significant correlation between the 4-week changes in CTX-II and cartilage erosion at week 9 (r = 0.64, P < 0.001). In postmenopausal women treated with levormeloxifene, the urinary excretion of CTX-II was decreased by approximately 50% and restored CTX-II levels to the premenopausal range. CONCLUSIONS: This study is the first to demonstrate that a SERM suppresses cartilage degradation in both rodents and humans, suggesting potential therapeutical benefits in the prevention of destructive joint diseases such as osteoarthritis.",

author = "Stephan Christgau and Tank{\'o}, {L{\'a}szl{\'o} B} and Cloos, {Paul A C} and Ulrik Mouritzen and Claus Christiansen and Jean-Marie Delaiss{\'e} and Pernille H{\o}egh-Andersen",

note = "Keywords: Aged; Analysis of Variance; Animals; Biopsy, Needle; Cartilage, Articular; Disease Models, Animal; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Estrogen Replacement Therapy; Female; Humans; Immunohistochemistry; Middle Aged; Osteoporosis, Postmenopausal; Ovariectomy; Postmenopause; Probability; Prognosis; Pyrrolidines; Rats; Rats, Sprague-Dawley; Risk Assessment; Selective Estrogen Receptor Modulators; Statistics, Nonparametric; Treatment Outcome",

year = "2004",

language = "English",

volume = "11",

pages = "508--18",

journal = "Menopause ",

issn = "1072-3714",

publisher = "Lippincott Williams & Wilkins",

number = "5",

}

TY - JOUR

T1 - Suppression of elevated cartilage turnover in postmenopausal women and in ovariectomized rats by estrogen and a selective estrogen-receptor modulator (SERM).

AU - Christgau, Stephan

AU - Tankó, László B

AU - Cloos, Paul A C

AU - Mouritzen, Ulrik

AU - Christiansen, Claus

AU - Delaissé, Jean-Marie

AU - Høegh-Andersen, Pernille

N1 - Keywords: Aged; Analysis of Variance; Animals; Biopsy, Needle; Cartilage, Articular; Disease Models, Animal; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Estrogen Replacement Therapy; Female; Humans; Immunohistochemistry; Middle Aged; Osteoporosis, Postmenopausal; Ovariectomy; Postmenopause; Probability; Prognosis; Pyrrolidines; Rats; Rats, Sprague-Dawley; Risk Assessment; Selective Estrogen Receptor Modulators; Statistics, Nonparametric; Treatment Outcome

PY - 2004

Y1 - 2004

N2 - OBJECTIVE: Several observational studies indicate that estrogen deficiency increases the incidence of osteoarthritis in postmenopausal women. To validate this observation, we investigated the effects of ovariectomy (OVX) on cartilage erosion in rats using histology and an established bio-assay of cartilage-specific collagen type II degradation products (CTX-II). Furthermore, we investigated whether estrogen and levormeloxifene, a selective estrogen-receptor modulator (SERM), can prevent the OVX-induced changes in cartilage degradation. The clinical relevance was assessed in postmenopausal women by measuring the changes in CTX-II during 12-month treatment with levormeloxifene versus placebo. DESIGN: Sixty 6-month-old rats were divided in five groups. One group was subjected to sham and the others to OVX, followed by treatment with vehicle alone, estradiol or 0.2 mg/kg/day or 5 mg/kg/day of levormeloxifene. The rats were treated for 9 weeks with biweekly blood and urine sampling for measurement of bone resorption and cartilage turnover. After study termination, hind knees were removed for histological analysis of erosions. The effect of levormeloxifene in post-menopausal women was assessed by measuring CTX-II in samples from 301 women who were participating in a phase II study of this SERM. RESULTS: OVX rats showed significant increases in the urinary excretion of CTX-II. After 9 weeks this was manifested as increased surface erosion of knee articular cartilage compared with sham-operated rats. Treatment with estrogen or levormeloxifene prevented the OVX-induced changes. There was a significant correlation between the 4-week changes in CTX-II and cartilage erosion at week 9 (r = 0.64, P < 0.001). In postmenopausal women treated with levormeloxifene, the urinary excretion of CTX-II was decreased by approximately 50% and restored CTX-II levels to the premenopausal range. CONCLUSIONS: This study is the first to demonstrate that a SERM suppresses cartilage degradation in both rodents and humans, suggesting potential therapeutical benefits in the prevention of destructive joint diseases such as osteoarthritis.

AB - OBJECTIVE: Several observational studies indicate that estrogen deficiency increases the incidence of osteoarthritis in postmenopausal women. To validate this observation, we investigated the effects of ovariectomy (OVX) on cartilage erosion in rats using histology and an established bio-assay of cartilage-specific collagen type II degradation products (CTX-II). Furthermore, we investigated whether estrogen and levormeloxifene, a selective estrogen-receptor modulator (SERM), can prevent the OVX-induced changes in cartilage degradation. The clinical relevance was assessed in postmenopausal women by measuring the changes in CTX-II during 12-month treatment with levormeloxifene versus placebo. DESIGN: Sixty 6-month-old rats were divided in five groups. One group was subjected to sham and the others to OVX, followed by treatment with vehicle alone, estradiol or 0.2 mg/kg/day or 5 mg/kg/day of levormeloxifene. The rats were treated for 9 weeks with biweekly blood and urine sampling for measurement of bone resorption and cartilage turnover. After study termination, hind knees were removed for histological analysis of erosions. The effect of levormeloxifene in post-menopausal women was assessed by measuring CTX-II in samples from 301 women who were participating in a phase II study of this SERM. RESULTS: OVX rats showed significant increases in the urinary excretion of CTX-II. After 9 weeks this was manifested as increased surface erosion of knee articular cartilage compared with sham-operated rats. Treatment with estrogen or levormeloxifene prevented the OVX-induced changes. There was a significant correlation between the 4-week changes in CTX-II and cartilage erosion at week 9 (r = 0.64, P < 0.001). In postmenopausal women treated with levormeloxifene, the urinary excretion of CTX-II was decreased by approximately 50% and restored CTX-II levels to the premenopausal range. CONCLUSIONS: This study is the first to demonstrate that a SERM suppresses cartilage degradation in both rodents and humans, suggesting potential therapeutical benefits in the prevention of destructive joint diseases such as osteoarthritis.

M3 - Journal article

C2 - 15356403

SN - 1072-3714

VL - 11

SP - 508

EP - 518

JO - Menopause

JF - Menopause

IS - 5

ER -